Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AER final rule for application OTCs

This article was originally published in The Tan Sheet

Executive Summary

FDA finalizes its interim final rule requiring application, or non-monograph, OTC products, and all Rx drugs to include toll-free numbers for reporting adverse events on packaging, effective Nov. 28. The rule, which also applies to private-label products, was mandated by the Food and Drug Administration Amendments Act of 2007 (1"The Tan Sheet" Jan. 21, 2008, p. 13). According to an Oct. 28 Federal Register notice, labels should explain the numbers are for AE reporting only. The compliance deadline is July 1, 2009

You may also be interested in...



FDAAA Requires Toll-Free Number For Side Effect Reports On Application OTCs

A rule mandated by the FDA reauthorization Congress passed in 2007 that requires a toll-free number for reporting side effects on packaging for non-monograph OTC products and all Rx drugs went into effect Jan.1, but the agency likely will not enforce it until 2009

FDA Clarifies Software Link In Abbott COVID-19 Lab Test Recall

The recall is related to the software’s mixing parameters, which may cause false positives if test samples contaminate each other.

Positive Signs For Valneva’s COVID-19 Vaccine, But Efficacy Data And Orders Still Lacking

Immunogenicity data from Valneva’s COV-COMPARE study are encouraging, but the inactivated vaccine will need proper efficacy data to gain a toehold in a crowded market.

Topics

UsernamePublicRestriction

Register

PS102249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel